{"_id": "650d0f75c9669d2e208ec2dd", "booleanRepresentation": "{\n    \"$and\":[\n        {\n            \"$and\": [\n                {\"over 70 years of age\"},\n                {\"consultation with the Medical Monitor\"}\n            ]\n        },\n        {\"historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS genomic alterations\"},\n        {\n            \"$or\": [\n                {\"1 additional line of therapy with appropriate targeted therapy for patients with actionable mutations (other than EGFR, ALK, or ROS genomic alterations)\"},\n                {\n                    \"$and\": [\n                        {\"documented radiographic disease progression on or after the first-line therapy\"},\n                        {\n                            \"$or\": [\n                                {\"concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab\"},\n                                {\"no more than 1 prior line if ICI and platinum-based chemotherapy were administered concurrently\"},\n                                {\"no more than 2 prior lines for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines\"}\n                            ]\n                        }\n                    ]\n                },\n                {\n                    \"$and\": [\n                        {\"LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination\"},\n                        {\"meet all eligibility criteria except documented disease progression\"},\n                        {\"intend to receive TIL therapy after disease progression\"}\n                    ]\n                },\n                {\"prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy\"},\n                {\"at least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1\"},\n                {\"adequate organ function\"},\n                {\"LVEF > 45%, NYHA Class 1\"},\n                {\"adequate pulmonary function\"},\n                {\"ECOG performance status of 0 or 1\"},\n                {\"patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy\"}\n            ]\n        },\n        {\n            \"$not\": {\n                \"$or\": [\n                    {\"EGFR driver mutation\"},\n                    {\"ALK driver mutation\"},\n                    {\"ROS driver mutation\"},\n                    {\"symptomatic, untreated brain metastases\"},\n                    {\"allogeneic organ transplant or prior cell therapy within the past 20 years\"},\n                    {\"any form of primary immunodeficiency\"},\n                    {\"systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent\"},\n                    {\"live or attenuated vaccination within 28 days prior to the start of treatment\"},\n                    {\"another primary malignancy within the previous 3 years\"},\n                    {\"participation in another interventional clinical study within 21 days\"}\n                ]\n            }\n        }\n    ]\n}", "nctId": "NCT04614103", "title": "A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer"}